1Semple MG, Dankert HM, Ebrahimi B, Correia JB, Booth JA, Stewart JP, et al. Severe respiratory syncytial virus bronchiolitis in infants is associated with reduced airway interferon gamma and substance P[J]. PLoS One, 2007, 2(10) :e1038.
2Everard ML, Swarbrick A, Wrightham M, McIntyre J, Dunkley C, James PD, et al. Analysis of cells obtained by bronchial lavage of infants with respiratory syncytial virus infection [ J]. Arch Dis Child, 1994, 71 (5) :428-432.
3胡亚美,江载芳,诸福堂.实用儿科学[M].第7版.北京:人民卫生出版社,2002.1514.
4Beck R, Elias N, Shoval S, Tov N, Talmon G, Godfrey S, et al. Computerized acoustic assessment of treatment efficacy of nebulized epinephrine and albuterol in RSV bronchiolitis[ J ]. BMC Pediatr, 2007, 7( 1 ) :22-27.
5MeNamara PS, Smyth RL. The pathogenesis of respiratory syncytial vires in childhood[J]. Br Med Bull, 2002, 61 (1) :13-28.
6Pitrez PM, Pinto LA, Machado DC, Tsukazan MT, Jones MH, Stein RT. Upper airway cellular pattern in infants with acute bronchiolitis: neutrophils or eosinophils? [J]. J Pediatr (Rio J), 2003,79 (5) :443-448.
7Behera AK, Kumar M, Matsuse H, Lockey RF, Mohapatra SS. Respiratory syncytial virus induces the expression of 5-1ipoxygenase and endothelin-1 in bronchial epithelial[ J]. Biochem Biophys Res Commun, 1998, 251 (3) :704-709.
1Fregonese L, Silvestri M, Sabatini F, et al. Cysteinyl leukotrienes induce human eosinophil locomotion and adhesion molecule expression via a Cys-LTI receptor mediated mechanism. Clin Exp Allergy, 2002, 32: 745-750.
2Braccioni F, Dorman SC, O′ byrne PM, et al. The effect of cysteinyl leukotrenes on growth of eosinophil proge from peripheral blood and bone marrow of atopic subjects. J Allergy Clin Immunol, 2002, 110:96-101.
3Murray J, Ward c, O′ Flaberty JT, et al. Role of leukotrenes in the regulation of human granulecyte behaviour: dissociation between agonist-induced activation and retardation of apoptosis. Br J Pharmacol, 2003, 139:388-398.
4Henderson WR Jr, Tang LO, Chu SJ, et al. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med, 2002, 165:108-116.
5Stelmach I, Jerzynska J, Kuna P. A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum ECP, sIL-2R, IL-4, and sICAM-1 in children with asthma. J Allergy Clin Immunol, 2002,109: 257-263.
6Stelmach I, Grzelewski T, Stelmach W, et al. Effect of triamcinolone acetonide, montelukast, nedocromil sodium and formoterol on eosinophil blood counts, ECP serum levels and clinical progression of asthma in children. Pol Merkuriusz Lek, 2002,12:208-213.
7Strauch E, Moske O, Thoma S, et al. A randomized controlled trial on the effect of montelukast on sputum eosinophil cationic protein in children with corticosteroid-dependent asthma. Pediatr Res, 2003, 54:198-203.
8Diamant Z, Grootendorst DC, Veselic-Charvat M, et al. The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma. Clin Exp Allergy, 1999, 29:42-51.
9Wu AY, Chik SC, Chan AW, et al. Anti-inflammatory effects of high-dose montelukast in an animal model of acute asthma. Clin Exp Allergy, 2003, 33:359-366.
10Finsnes F, Lyberg T, Christensen G, et al. Leukotriene antagonism reduces the generation of endothelin-1 and IFN-γand inhibits eosinophilic airway inflammation. Respir Med, 2002,96: 901-906.
